The CFTR modulator drug class may provide pharmacological approaches to managing common and persistent type 2 inflammation in CF via epithelial and CD4+ T cell mechanisms, while more broadly representing a new class of therapies to be repurposed for allergic disease. This evidence concerns the gene CD4 and allergic disease.